Vitrification
Although most living organisms are composed of large amounts of water, it is not inevitable that freezing these organisms results in ice-formation. Among amphibians and insects that can tolerate freezing, there is wide variation in the amount of freezing they can tolerate. Species of frogs can spend days or weeks "with as much as 65 percent of their total body water as ice". Some amphibians achieve their protection due to the glycerol manufactured by their livers. Glycerol is "antifreeze", it reduces ice formation and lowers freezing point. Glycerol (glycerin), like ethylene glycol (automobile anti-freeze) is cryoprotectants. The sugar glucose is also cryoprotectants — and arctic frogs have a special form of insulin that accelerates glucose release and absorption into cells as temperatures approach freezing. Cryoprotectants can make water harden like glass — with no crystal formation — a process called Vitrification. Freezing-damage to cells is due to the formation of ice-crystals. Entire organs can be solidified and stored at temperatures as low as -140° C. Scientists are working on ways to reduce the toxicity of the cryoprotectants used to make water vitrify to allow banking of organs for transplantation. At Alcor, we are optimistic that the toxicity that still does occur with vitrification of human organs will be reversible with future molecular repair technology.
- Vitrification versus slow freezing
- Short term and Long term tissue preservation
- Human blastocyst vitrification and warming
- Biosafety of vitrification - the issue of contamination using an open system
- Effect of different vitrification solutions and procedures
Related Conference of Vitrification
19th International Conference on Human Genomics and Genomic Medicine
22nd World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
17th International Conference on Human Genetics and Genetic Diseases
Vitrification Conference Speakers
Recommended Sessions
- Bio specimen and Biorepository
- Tissue engineering
- Bio preservation and its Advances
- Biobank sustainability: current status and future prospects
- Biobanking & expertise networks
- Biobanking for rare disease
- Cryopreservation methods
- Ethical issues in biobanking
- Fertility preservation
- Human cancer biobank
- Next generation Biobanking
- Quality management in Biobanking
- Scaffolds for Tissue Engineering
- Stem cell and Stem cell biobanking
- Vitrification
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2026 (UAE)
- Advanced Imaging and Single-Cell Technologies - cellscience-cs-2027 (UK)
- Animal Genetics - Genome 2027 (Germany)
- Artificial Intelligence in Cell and Molecular Research - cellscience-cs-2027 (UK)
- Bioinformatics and Computational Biology - cellscience-cs-2027 (UK)
- Bioinformatics and Computational Biology - Genome 2027 (Germany)
- Biomarkers and Microarrays - Genome 2027 (Germany)
- Biotechnology and Molecular Therapeutics - cellscience-cs-2027 (UK)
- Cancer and stem cells - CRISPR 2026 (UAE)
- Cancer Cell Biology and Molecular Oncology - cellscience-cs-2027 (UK)
- Cancer Genomics - Genome 2027 (Germany)
- Cell Biology and Cellular Mechanisms - cellscience-cs-2027 (UK)
- Cellular Metabolism and Metabolic Biology - cellscience-cs-2027 (UK)
- Cellular signaling and Signal Transduction - cellscience-cs-2027 (UK)
- Clinical genomics - Genome 2027 (Germany)
- Comparative Genomics - Genome 2027 (Germany)
- CRISPR technologies and society - CRISPR 2026 (UAE)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2026 (UAE)
- Emerging Technologies and Future Directions in Cell Science - cellscience-cs-2027 (UK)
- Epigenomics and Epigenetics - Genome 2027 (Germany)
- Functional Genomics - Genome 2027 (Germany)
- Gene Editing and Genetic Engineering - Genome 2027 (Germany)
- Genetic Disorder - Genome 2027 (Germany)
- Genetics, Genomics and Genome Biology - cellscience-cs-2027 (UK)
- Genome editing and gene regulation in human health - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2026 (UAE)
- Genome Editing Methods and Novel Tools - CRISPR 2026 (UAE)
- Genomic Instability - Genome 2027 (Germany)
- Genomic Medicine - Genome 2027 (Germany)
- Horizons of CRISPR biology - CRISPR 2026 (UAE)
- Immunology and Cellular Immunity - cellscience-cs-2027 (UK)
- Microbial Genomics - Genome 2027 (Germany)
- Molecular Biology and Gene Regulation - cellscience-cs-2027 (UK)
- Molecular Diagnostics and Biomarkers - cellscience-cs-2027 (UK)
- Molecular Medicine and Translational Research - cellscience-cs-2027 (UK)
- Molecular Microbiology and Host–Pathogen Interactions - cellscience-cs-2027 (UK)
- Next generation sequencing - Genome 2027 (Germany)
- Nutrigenomics - Genome 2027 (Germany)
- Personalized and Regenerative Medicine - Genome 2027 (Germany)
- Pharmacogenomics - Genome 2027 (Germany)
- Plant and Animal Biotechnology - CRISPR 2026 (UAE)
- Plant Genomics and Molecular Pharming - Genome 2027 (Germany)
- Stem Cell Biology and Regenerative Medicine - cellscience-cs-2027 (UK)
- Structural Biology and Bioinformatics - CRISPR 2026 (UAE)
- Structural Genomics - Genome 2027 (Germany)
- Therapeutic Genome Editing - CRISPR 2026 (UAE)
- Trends in Genomics and Pharmacogenomics - Genome 2027 (Germany)

